The Effects of Omega-3 Fatty Acids on Aspirin Resistance

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if omega-3 fatty acids enhance the antiplatelet effects of aspirin.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Rochester
• Collaborators: American College of Clinical Pharmacy; Cornell University; GlaxoSmithKline
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Willing to participate by providing informed consent and committing to complete the study. This includes adhering to the study diet.

• No chronic disease by history and based on a complete blood count and comprehensive metabolic profile.

• Commitment to not taking aspirin, non-steroidal anti-inflammatory medications, and to limit fish intake to ≤2 meals during the 7 days prior to each CRC study period. They will also need to abstain from taking a list of over-the-counter medications that include aspirin. For the duration of the study, they will also be asked to abstain from taking fish and flax seed oil supplements.

Exclusion Criteria:

• Reports the presence of chronic disease (e.g. cardiovascular, renal, hepatic, neurodegenerative, neoplastic, metabolic {diabetes}, hypertension).

• Reports taking a systemic medication chronically.

• History of serious adverse reaction or allergy to aspirin or fish oil.

• Baseline platelet count <100 000 or >500 000, hematocrit <30%, or white blood cell count >20 000.

• Any abnormality from a screening CBC and complete blood count that suggests acute or chronic disease.

• Nicotine user.

• History of alcohol abuse

• Pregnancy by history or urine/serum pregnancy test

• History of intestinal malabsorption syndrome including gastric bypass surgery